Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

• Sponsor: Sheba Medical Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT00229385
• Collaborator: (none)
• Enrollment: 45
• Location: 1
• Arms: 2
• Duration (Months): 51
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia; Obsessive Compulsive Disorder	Drug: Ziprasidone	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 45 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Diagnostic
• Official Title: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)
• Study Start Date: Jan 1, 2006
• Actual Primary Completion Date: Apr 1, 2008
• Actual Study Completion Date: Apr 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: 1	Drug: Ziprasidone; 40-80 mg BID
Active Comparator: 2	Drug: Ziprasidone; 40-80 mg BID

Outcome Measures

Primary Outcome Measures

1. YBOCS [8 weeks]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosis of Schizophrenia and OCD for at least 6 months

• Minimum score of 14 on YBOCS

• Minimum score of 60 on PANSS

• Diagnosis of Schizophrenia without OC symptoms

Exclusion Criteria:

• Patients who are already being treated with ziprasidone

• Diagnosis of schizophreniform disorder

• Organic brain syndrome, mental retardation and pervasive developmental disorder

• Patients having any significantly cardiovascular illness or electrolyte imbalance

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Chaim Sheba Medical Center	Ramat-Gan		Israel	52621

Sponsors and Collaborators

• Sheba Medical Center

Investigators

• Principal Investigator: Joseph Zohar, MD, Tel Aviv University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Prof. Joseph Zohar, Prof. Joseph Zohar, Sheba Medical Center
• ClinicalTrials.gov Identifier: NCT00229385
• Other Study ID Numbers: SHEBA-03-3061-JS-CTIL
• First Posted: Sep 29, 2005
• Last Update Posted: Dec 31, 2013
• Last Verified: Dec 1, 2013

• Additional relevant MeSH terms: Schizophrenia; Compulsive Personality Disorder; Obsessive-Compulsive Disorder; Ziprasidone

Study Results

No Results Posted as of Dec 31, 2013